• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纯合子家族性高胆固醇血症患者临床、生化及基因评估的真实世界经验

A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia.

作者信息

Di Taranto Maria Donata, Giacobbe Carola, Buonaiuto Alessio, Calcaterra Ilenia, Palma Daniela, Maione Giovanna, Iannuzzo Gabriella, Di Minno Matteo Nicola Dario, Rubba Paolo, Fortunato Giuliana

机构信息

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, 80131 Naples, Italy.

CEINGE S.C.a r.l. Biotecnologie Avanzate, 80131 Naples, Italy.

出版信息

J Clin Med. 2020 Jan 14;9(1):219. doi: 10.3390/jcm9010219.

DOI:10.3390/jcm9010219
PMID:31947532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7019873/
Abstract

Homozygous familial hypercholesterolemia (HoFH), the severest form of familial hypercholesterolemia (FH), is characterized by very high LDL-cholesterol levels and a high frequency of coronary heart disease. The disease is caused by the presence of either a pathogenic variant at homozygous status or of two pathogenic variants at compound heterozygous status in the , , genes. We retrospectively analyzed data of 23 HoFH patients (four children and 19 adults) identified during the genetic screening of 724 FH patients. Genetic screening was performed by sequencing FH causative genes and identifying large rearrangements of . Among the HoFH patients, four out of 23 (17.4%) were true homozygotes, whereas 19 out of 23 (82.6%) were compound heterozygotes for variants in the gene. Basal LDL-cholesterol was 12.9 ± 2.9 mmol/L. LDL-cholesterol levels decreased to 7.2 ± 1.8 mmol/L when treated with statin/ezetimibe and to 5.1 ± 3.1 mmol/L with anti- antibodies. Homozygous patients showed higher basal LDL-cholesterol and a poorer response to therapy compared with compound heterozygotes. Since 19 unrelated patients were identified in the Campania region (6,000,000 inhabitants) in southern Italy, the regional prevalence of HoFH was estimated to be at least 1:320,000. In conclusion, our results revealed a worse phenotype for homozygotes compared with compound heterozygotes, thereby highlighting the role of genetic screening in differentiating one genetic status from the other.

摘要

纯合子家族性高胆固醇血症(HoFH)是家族性高胆固醇血症(FH)最严重的形式,其特征是低密度脂蛋白胆固醇水平极高且冠心病发病率高。该疾病是由 、 、 基因中纯合状态的致病变异或复合杂合状态的两个致病变异引起的。我们回顾性分析了在对724例FH患者进行基因筛查期间确定的23例HoFH患者(4名儿童和19名成人)的数据。通过对FH致病基因进行测序并鉴定 的大片段重排来进行基因筛查。在HoFH患者中,23例中有4例(17.4%)为真正的纯合子,而23例中有19例(82.6%)为 基因变异的复合杂合子。基础低密度脂蛋白胆固醇为12.9±2.9 mmol/L。使用他汀类药物/依折麦布治疗时,低密度脂蛋白胆固醇水平降至7.2±1.8 mmol/L,使用抗 抗体治疗时降至5.1±3.1 mmol/L。与复合杂合子相比,纯合子患者的基础低密度脂蛋白胆固醇更高,对治疗的反应更差。由于在意大利南部坎帕尼亚地区(600万居民)发现了19例无亲缘关系的患者,因此HoFH的地区患病率估计至少为1:320,000。总之,我们的结果显示纯合子的表型比复合杂合子更差,从而突出了基因筛查在区分这两种遗传状态方面的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378c/7019873/30acfa8b6cbb/jcm-09-00219-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378c/7019873/e1805d9f50bb/jcm-09-00219-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378c/7019873/30acfa8b6cbb/jcm-09-00219-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378c/7019873/e1805d9f50bb/jcm-09-00219-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378c/7019873/30acfa8b6cbb/jcm-09-00219-g002.jpg

相似文献

1
A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia.纯合子家族性高胆固醇血症患者临床、生化及基因评估的真实世界经验
J Clin Med. 2020 Jan 14;9(1):219. doi: 10.3390/jcm9010219.
2
The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study.儿童纯合子家族性高胆固醇血症的临床和分子多样性:来自临床纯合子高胆固醇血症基因研究(GoTCHA)的结果。
J Clin Lipidol. 2019 Mar-Apr;13(2):272-278. doi: 10.1016/j.jacl.2018.12.003. Epub 2018 Dec 19.
3
Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.西班牙的纯合子家族性高胆固醇血症:患病率及表型-基因型关系
Circ Cardiovasc Genet. 2016 Dec;9(6):504-510. doi: 10.1161/CIRCGENETICS.116.001545. Epub 2016 Oct 26.
4
Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia.通过长读测序在临床诊断为杂合子家族性高胆固醇血症的患者中鉴定纯合子家族性高胆固醇血症。
Circ Genom Precis Med. 2023 Apr;16(2):e003887. doi: 10.1161/CIRCGEN.122.003887. Epub 2023 Mar 24.
5
Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.《伊比利亚美洲地区同型合子家族性高胆固醇血症成人和儿童的表型、临床和分子特征》
Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2508-2515. doi: 10.1161/ATVBAHA.120.313722. Epub 2020 Aug 6.
6
Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.意大利家族性高胆固醇血症纯合子患者:临床和分子特征。
Atherosclerosis. 2020 Nov;312:72-78. doi: 10.1016/j.atherosclerosis.2020.08.027. Epub 2020 Sep 9.
7
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.意大利家族性高胆固醇血症患者的突变谱:LIPIGEN研究的新结果。
Atheroscler Suppl. 2017 Oct;29:17-24. doi: 10.1016/j.atherosclerosissup.2017.07.002.
8
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.纯合子家族性高胆固醇血症患者携带相同的 LDLR(低密度脂蛋白受体)突变,其表达可变:对依洛尤单抗疗效的影响。
Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):592-598. doi: 10.1161/ATVBAHA.117.310217. Epub 2017 Dec 28.
9
Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.下一代测序技术用于鉴定导致常染色体显性遗传性高胆固醇血症并伴有冠心病风险增加的新型基因变异。
Gene. 2015 Jul 1;565(1):76-84. doi: 10.1016/j.gene.2015.03.064. Epub 2015 Apr 1.
10
Screening of LDLR and APOB gene mutations in Mexican patients with homozygous familial hypercholesterolemia.对墨西哥家族性高胆固醇血症纯合子患者的 LDLR 和 APOB 基因突变进行筛查。
J Clin Lipidol. 2018 May-Jun;12(3):693-701. doi: 10.1016/j.jacl.2018.02.015. Epub 2018 Mar 1.

引用本文的文献

1
Lipoprotein lipase deficiency: heterozygotes match homozygotes in severity.脂蛋白脂肪酶缺乏症:杂合子在严重程度上与纯合子相当。
Arch Med Sci. 2025 Jun 25;21(3):750-756. doi: 10.5114/aoms/201448. eCollection 2025.
2
Gene Mutation in Patients with Familial Hypercholesterolemia and Response to Alirocumab Treatment-A Single-Centre Analysis.家族性高胆固醇血症患者的基因突变及对阿利西尤单抗治疗的反应——一项单中心分析
J Clin Med. 2024 Sep 22;13(18):5615. doi: 10.3390/jcm13185615.
3
Impact of 12-SNP and 6-SNP Polygenic Scores on Predisposition to High LDL-Cholesterol Levels in Patients with Familial Hypercholesterolemia.

本文引用的文献

1
Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.功能性分析 LDLR(低密度脂蛋白受体)变异在患者淋巴细胞中,以评估依维莫司在杂合子家族性高胆固醇血症患者中对 LDLR 活性谱的影响。
Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2248-2260. doi: 10.1161/ATVBAHA.119.313051. Epub 2019 Oct 3.
2
A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study.一项关于同型家族性高胆固醇血症患者心血管生存的跨国调查:中国-罗马研究。
J Clin Lipidol. 2019 Jul-Aug;13(4):608-617. doi: 10.1016/j.jacl.2019.05.002. Epub 2019 May 12.
3
12个单核苷酸多态性和6个单核苷酸多态性多基因评分对家族性高胆固醇血症患者高LDL-胆固醇水平易感性的影响。
Genes (Basel). 2024 Apr 6;15(4):462. doi: 10.3390/genes15040462.
4
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.依洛尤单抗在治疗儿童纯合子家族性高胆固醇血症中的应用。
Circulation. 2024 Jan 30;149(5):343-353. doi: 10.1161/CIRCULATIONAHA.123.065529. Epub 2023 Oct 20.
5
Genetic Heterogeneity of Familial Hypercholesterolemia: Repercussions for Molecular Diagnosis.家族性高胆固醇血症的遗传异质性:对分子诊断的影响。
Int J Mol Sci. 2023 Feb 6;24(4):3224. doi: 10.3390/ijms24043224.
6
Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment.Ⅰ型戈谢病患者酶替代治疗下的营养状况评估。
Nutrients. 2022 Aug 3;14(15):3180. doi: 10.3390/nu14153180.
7
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.世界范围内纯合子家族性高胆固醇血症的经验:回顾性队列研究。
Lancet. 2022 Feb 19;399(10326):719-728. doi: 10.1016/S0140-6736(21)02001-8. Epub 2022 Jan 28.
8
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.脂蛋白吸附术和lomitapide 治疗纯合子家族性高胆固醇血症(HoFH)的长期疗效:跨国回顾性调查。
Orphanet J Rare Dis. 2021 Sep 8;16(1):381. doi: 10.1186/s13023-021-01999-8.
9
Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement.家族性高胆固醇血症的基因谱及其与临床表现的相关性:对改善诊断的意义。
Clin Genet. 2021 Nov;100(5):529-541. doi: 10.1111/cge.14036. Epub 2021 Aug 3.
10
Lipoprotein metabolism in familial hypercholesterolemia.家族性高胆固醇血症中的脂蛋白代谢。
J Lipid Res. 2021;62:100062. doi: 10.1016/j.jlr.2021.100062. Epub 2021 Mar 3.
Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia.儿童纯合子家族性高胆固醇血症患者使用洛美他派的真实世界结局。
Adv Ther. 2019 Jul;36(7):1786-1811. doi: 10.1007/s12325-019-00985-8. Epub 2019 May 17.
4
The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study.儿童纯合子家族性高胆固醇血症的临床和分子多样性:来自临床纯合子高胆固醇血症基因研究(GoTCHA)的结果。
J Clin Lipidol. 2019 Mar-Apr;13(2):272-278. doi: 10.1016/j.jacl.2018.12.003. Epub 2018 Dec 19.
5
Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio.家族性高胆固醇血症儿科人群的血脂谱和遗传状况:探讨 LDL/HDL 比值。
Clin Chem Lab Med. 2019 Jun 26;57(7):1102-1110. doi: 10.1515/cclm-2018-1037.
6
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study.荷兰脂质诊所网络评分在意大利 FH 人群中的表现评估:LIPIGEN 研究。
Atherosclerosis. 2018 Oct;277:413-418. doi: 10.1016/j.atherosclerosis.2018.08.013.
7
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.家族性高胆固醇血症的临床基因检测:美国心脏病学会科学专家组。
J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. doi: 10.1016/j.jacc.2018.05.044.
8
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia.阿利西尤单抗在双重杂合子、复合杂合子或纯合子家族性高胆固醇血症患者中的疗效。
J Clin Lipidol. 2018 Mar-Apr;12(2):390-396.e8. doi: 10.1016/j.jacl.2017.12.008. Epub 2017 Dec 28.
9
Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis.分析与家族性高胆固醇血症相关的 LDLR、APOB 和 PCSK9 常见变异:ACMG 指南的应用及其对家族性高胆固醇血症诊断的影响。
Genet Med. 2018 Jun;20(6):591-598. doi: 10.1038/gim.2017.151. Epub 2017 Oct 26.
10
Familial hypercholesterolaemia.家族性高胆固醇血症。
Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/nrdp.2017.93.